Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bearish Momentum

Open Interest and Volume Dynamics

On 1 April 2026, Zydus Lifesciences (symbol: ZYDUSLIFE) recorded an open interest (OI) of 13,696 contracts, up from 12,277 the previous day, marking an increase of 1,419 contracts or 11.56%. This rise in OI is significant given the stock’s concurrent price decline of 0.92% on the day, underperforming its Pharmaceuticals & Biotechnology sector by 0.38%. The total futures value stood at ₹9,221.84 lakhs, while options value was substantially higher at ₹2,533.79 crores, reflecting active derivatives trading interest.

Volume data further corroborates this trend, with 4,215 contracts traded in futures on the day. Notably, the weighted average price of traded volumes was closer to the day’s low, indicating that the bulk of trading occurred near lower price levels. This pattern often suggests selling pressure or profit booking by participants.

Price Performance and Moving Averages

Zydus Lifesciences has been on a downward trajectory, falling for three consecutive sessions with a cumulative loss of 4.28%. The stock’s intraday high of ₹900 represented a 3.31% rise but was not sustained, as prices closed lower. Importantly, the share price is trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—highlighting a bearish technical setup. This persistent weakness in price action is likely influencing the derivatives market, where participants may be positioning for further downside.

Investor Participation and Liquidity

Delivery volumes on 30 March surged to 5.74 lakh shares, a 72.84% increase over the five-day average, signalling rising investor participation despite the stock’s recent losses. This heightened delivery volume suggests that long-term investors may be accumulating shares at lower levels or that short sellers are covering positions. The stock’s liquidity remains robust, with a trade size capacity of approximately ₹1.38 crore based on 2% of the five-day average traded value, ensuring ease of entry and exit for market participants.

Market Positioning and Directional Bets

The simultaneous rise in open interest and volume amid falling prices typically indicates that new short positions are being established, or existing shorts are being added to. This suggests that traders are increasingly bearish on Zydus Lifesciences in the near term. The derivatives market’s elevated options value, exceeding ₹2,533 crores, further points to active hedging and speculative activity, with participants possibly favouring put options or protective strategies.

Given the stock’s downgrade from a Hold to a Sell rating on 1 December 2025, with a Mojo Score of 48.0, the market sentiment appears to have deteriorated. The mid-cap pharmaceutical company’s current valuation and technical weakness may be prompting investors and traders to reassess their exposure, favouring defensive or exit strategies.

Sector and Benchmark Comparison

While Zydus Lifesciences declined by 0.93% on the day, the Pharmaceuticals & Biotechnology sector fell by a lesser 0.37%, and the broader Sensex advanced by 1.54%. This relative underperformance underscores the stock-specific pressures weighing on Zydus. Investors should note that the sector’s resilience contrasts with the stock’s weakness, signalling potential company-specific challenges or profit-taking.

Outlook and Investor Considerations

With the stock trading below all major moving averages and exhibiting a three-day losing streak, the technical outlook remains bearish. The surge in open interest and volume in derivatives markets confirms that traders are positioning for further downside or volatility. Investors should monitor upcoming corporate developments, earnings announcements, and sectoral trends closely before increasing exposure.

Long-term investors might view the recent delivery volume spike as an opportunity to accumulate selectively, but caution is warranted given the current negative momentum and downgrade status. Active traders could consider strategies that benefit from volatility or downside moves, such as protective puts or short futures positions.

Summary

Zydus Lifesciences Ltd’s recent surge in open interest by 11.56% amid falling prices and rising delivery volumes highlights a shift towards bearish market positioning. The stock’s underperformance relative to its sector and the broader market, combined with its downgrade to a Sell rating and weak technical indicators, suggests caution for investors and traders alike. While increased investor participation through delivery volumes may indicate some accumulation, the derivatives market activity points to heightened volatility and potential downside risks in the near term.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today